-
Synovus Q2 Earnings Beat Estimates, Revenues Fall Y/Y
2024 Jul 18, 12:41pm | 700Synovus Financial Corp. (NYSE: SNV) reported second-quarter 2024 adjusted earnings per share of $1.16, which surpassed the Zacks Consensus Estimate of 96 cents. Adjusted earnings were the same as that reported in the year-ago quarter. Results benefited from a fall in expenses and provisions for...
-
U.S. Silica's Acquisition by Apollo Gets Shareholders' Nod
2024 Jul 17, 3:27pm | 633U.S. Silica Holdings, Inc. (NYSE: SLCA) announced the shareholder approval of its acquisition by funds managed by affiliates of Apollo, a premier investment firm. This all-cash transaction was approved during a special meeting of the company's stockholders on Jul 16, 2024. The closing of the...
-
WAFD's Q3 Earnings Beat Estimates, Revenues Rise on LBC Deal
2024 Jul 17, 3:26pm | 758WaFd, Inc.'s (NASDAQ: WAFD) third-quarter fiscal 2024 (ended Jun 30) adjusted earnings of 76 cents per share handily surpassed the Zacks Consensus Estimate of 59 cents. Also, the bottom line rose 4.1% sequentially. The quarter marked the first full quarter after the completion of the...
-
Progressive's Q2 Earnings Beat, Premiums Rise Y/Y
2024 Jul 17, 12:44pm | 584The Progressive Corporation's (NYSE: PGR) second-quarter 2024 earnings per share of $2.65 beat the Zacks Consensus Estimate of $1.99. The bottom line improved more than five times year over year. Operating revenues of $18.3 billion beat the Zacks Consensus Estimate by 1.4% and increased 18.9%...
-
Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data
2024 Jul 17, 11:48am | 686Shares of Lexeo Therapeutics (NASDAQ: LXEO) lost 26% on Monday after it reported positive interim data from two cohorts of the phase I/II SUNRISE-FA study evaluating LX2006, an investigational gene therapy for treating Friedreich ataxia (FA) cardiomyopathy. Data from the SUNRISE-FA study showed...
-
Catalent Expands Its Facility Capabilities in Germany
2024 Jul 17, 11:42am | 785Catalent, Inc. (NYSE: CTLT) announced that it has completed the expansion of its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent's flagship European facility, provides comprehensive clinical supply services, including packaging, storage and distribution. The...
-
Bank First Corporation Tops Q2 Earnings and Revenue Estimates
2024 Jul 17, 11:39am | 661Bank First Corporation (NASDAQ: BFC) came out with quarterly earnings of $1.56 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.42 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an...
-
Dow Jones Closes At Record High As Traders Turn Bullish Amid Hopes Of Fed Cutting Rates In September
2024 Jul 17, 3:14am | 467The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, with the index remaining in the “Greed” zone on Tuesday. U.S. stocks closed higher on Tuesday, with the Dow Jones index surging to an all-time high and settling at a record level. Traders now see...
-
ASML Beats Q2 Earnings Expectations With Strong China Sales, AI Chip Demand
2024 Jul 17, 2:18am | 680ASML Holding NV (NASDAQ:ASML), the leading supplier of equipment to computer chip manufacturers, has exceeded second-quarter earnings forecasts, driven by robust sales in China and a surge in new bookings. What Happened: The Dutch company reported a second-quarter net income of 1.6 billion euros ($...
-
Halliburton Q2 Earnings on Deck: Here's How It Will Fare
2024 Jul 16, 2:39pm | 911Halliburton Company (NYSE: HAL) is set to release second-quarter results on Jul 19. The current Zacks Consensus Estimate for the to-be-reported quarter is a profit of 80 cents per share on revenues of $6 billion. Let's delve into the factors that might have influenced the oilfield service firm...
-
Lisata Stock Rallies More Than 30% YTD: Here's Why
2024 Jul 16, 1:38pm | 768Lisata Therapeutics, Inc.'s (NASDAQ: LSTA) lead pipeline candidate is certepetide (formerly known as LSTA1), which is being developed for treating a range of solid tumors. Earlier this month, the company announced upbeat data from a preclinical study evaluating certepetide for treating...
-
Immutep Up as Combo Therapy Meets Carcinoma Study Goals
2024 Jul 15, 3:57pm | 760Immutep Limited (NASDAQ: IMMP) jumped 14.9% after it announced positive results from cohort B of the late-stage TACTI-003 (KEYNOTE-PNC-34) study. The study evaluated the combination of its pipeline candidate eftilagimod alfa (efti) and Merck's (NYSE: MRK) Keytruda (pembrolizumab) as a...
-
Quest Diagnostics Set to Acquire OhioHealth's Lab Services
2024 Jul 15, 3:56pm | 892Quest Diagnostics (NYSE: DGX) recently announced a definitive agreement to purchase the select assets of OhioHealth's outreach laboratory services business. The transaction will expand access to the company's cost-effective and advanced laboratory services in Ohio. The transaction is likely...
-
Bank of America, Schwab, Morgan Stanley: What To Expect From Tuesday's Earnings
2024 Jul 15, 3:42pm | 592Bank of America Corporation (NYSE:BAC), Charles Schwab Corporation (NYSE:SCHW) and Morgan Stanley (NYSE:MS) are expected to report their second-quarter earnings on Tuesday. Analysts expect Bank of America to post earnings per share (EPS) of 80 cents alongside $22.52 billion in revenue for the...
-
Low Market Volatility to Hurt Schwab's Q2 Earnings
2024 Jul 12, 2:05pm | 902Charles Schwab (NYSE: SCHW) is scheduled to report second-quarter 2024 results on Jul 16, before market open. While the company's earnings are expected to have declined in the quarter on a year-over-year basis, revenues are anticipated to have improved. In the first quarter of 2024, Schwab'...
Coverage of Earnings Beats.